anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In randomised controlled trials, the outcome of interest could be recurrent events, such as hospitalisations for heart failure. If mortality rates are non-negligible, both recurrent events and competing terminal events need to be addressed when formulating the estimand and statistical analysis is no longer trivial. In order to design future trials with primary recurrent event endpoints with competing risks, it is necessary to be able to perform power calculations to determine sample sizes. This paper introduces a simulation-based approach for power estimation based on a proportional means model for recurrent events and a proportional hazards model for terminal events. The simulation procedure is presented along with a discussion of what the user needs to specify to use the approach. The method is flexible and based on marginal quantities which are easy to specify. However, the method introduces a lack of a certain type of dependence. This is explored in a sensitivity analysis which suggests that the power is robust in spite of that. Data from a randomised controlled trial, LEADER, is used as the basis for generating data for a future trial. Finally, potential power gains of recurrent event methods as opposed to first event methods are discussed.
The Applicant has discovered a number of peptides that are capable of phosphorylating ribosomal protein S6 (rpS6) across a range of concentrations in in-vitro cell assays in a dose-dependent manner. RPS6 is a key substrate for protein kinases and is phosphorylated by growth factors and mitogens during in cell growth and cell division. This is a key step in the synthesis of new proteins in skeletal muscle tissue. The peptides described also have the ability to reduce the expression of mRNA Transcripts (TRIM63 and FBXO32) that are directly linked to increase protein degradation, resulting in progressive Skeletal Muscle Atrophy. In addition, increases in muscular atrophy are linked with systemic rise in circulating TNF?. The peptides described herein also lead to the reduced expression of TNF? in circulating immune cells. The peptides may be used to promote muscle growth and muscle health in subjects that exhibit muscle atrophy, for example elderly subjects, physically inactive people, and subjects that have indications characterised by muscle atrophy (i.e. MS and Polio).
Twelve healthy volunteers will undergo antroduodenojejunal manometry. Baseline recording with infusion of saline for 1 hour is compared with infusion of GLP-1 0.7 and 1.2 pmol per kg minute for another 1 hour. Plasma GLP-1 and GLP-2 is measured by RIA. Responses to GLP-1 will be measured after food intake as prandial response to GLP-1. The outcome will be evaluated as change in motility index from baseline to meal-stimulated conditions and during influence of GLP-1. Further in vitro studies of gastrointestinal muscle strips, precontracted with bethanechol or electric field stimulation, are planned to investigate the response to GLP-1 or GLP-1 analogue ROSE-010. GLP-1 and GLP-2 receptor immunoreactivity is localized by immunohistochemistry. Receptor mediated mechanisms are studied with GLP-1 receptor blocker exendin(9-39)amide, nitro-monomethyl arginine to block nitric oxide synthase and tetrodotoxin to block sodium channels and nerve conduction.
Local anesthesia with 0.25% 20 mL bupivacaine will be given extrapedicular part of the fractured vertebra by the surgeon. At the same time, intravenous 0.1 mg/kg midazolam, 0.3 mg/kg ketamine and 25-100 mcg/kg/min propofol will be administered to achieve sedation and analgesia.
BACKGROUND: Postoperative hypoxemia and pulmonary complications remain a frequent event after on-pump cardiac surgery and mostly characterized by pulmonary atelectasis. Surfactant dysfunction or hyposecretion happens prior to atelectasis formation, and sigh represents the strongest stimulus for surfactant secretion. The role of sigh breaths added to conventional lung protective ventilation in reducing postoperative hypoxemia and pulmonary complications among cardiac surgery is unknown.
METHODS: The perioperative sigh ventilation in cardiac surgery (E-SIGHT) trial is a single-center, two-arm, randomized controlled trial. In total, 192 patients scheduled for elective cardiac surgery with cardiopulmonary bypass (CPB) and aortic cross-clamp will be randomized into one of the two treatment arms. In the experimental group, besides conventional lung protective ventilation, sigh volumes producing plateau pressures of 35 cmH2O (or 40 cmH2O for patients with body mass index > 35 kg/m2) delivered once every 6 min from intubation to extubation. In the control group, conventional lung protective ventilation without preplanned recruitment maneuvers is used. Lung protective ventilation (LPV) consists of low tidal volumes (6-8 mL/kg of predicted body weight) and positive end-expiratory pressure (PEEP) setting according to low PEEP/FiO2 table for acute respiratory distress syndrome (ARDS). The primary endpoint is time-weighted average SpO2/FiO2 ratio during the initial post-extubation hour. Main secondary endpoint is the severity of postoperative pulmonary complications (PPCs) computed by postoperative day 7.
DISCUSSION: The E-SIGHT trial will be the first randomized controlled trial to evaluate the impact of perioperative sigh ventilation on the postoperative outcomes after on-pump cardiac surgery. The trial will introduce and assess a novel perioperative ventilation approach to mitigate the risk of postoperative hypoxemia and PPCs in patients undergoing cardiac surgery. Also provide the basis for a future larger trial aiming at verifying the impact of sigh ventilation on postoperative pulmonary complications.
TRIAL REGISTRATION: ClinicalTrials.gov NCT06248320. Registered on January 30, 2024. Last updated February 26, 2024.
This group will receive an intervention on food waste management and fruit and vegetable replacement to increase diet quality while avoiding an increase in calories. Both groups will obtain free fruit and vegetable boxes and will use the FoodImage app to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
PURPOSE:To obtain an agent for the cleaning of human body, capable effectively removing the stains, cleaning the human body leaving the useful lipid, and giving excellent feeling, luster, and smoothness to the skin, by mixing a phospholipid with a polymeric compound and a water-soluble or water-dispersible compound. CONSTITUTION:The objective body-cleaning agent can be produced by mixing (A) a phospholipid (e.g. soybean phospholipid) with (B) a polymeric compound (e.g. extract of algae, CMC, etc.) and (C) a water-soluble or water-dispersible compound (e.g. alkaline earth metal compound, monosaccharide, etc.). A phospholipid has only poor cleaning activity by single use, however, the cleaning effect can be increased remarkably to the level of conventional detergent when combined with a polymeric compound and a water-soluble or water-dispersible compound. Furthermore, it leaves the useful lipid on the skin, and gives cleaned skin with excellent feeling, luster and smoothness compared with conventional detergent.
PURPOSE:To produce an easily absorbable glycoside extract of ginkgo leaf in improved extraction efficiency by extracting ginkgo leaf with water or a water/ethanol mixture and carrying out sugar transfer of a water-insoluble component of the extracted liquid or a liquid containing dried extract using a specific sugar-transfer method. CONSTITUTION:Dried and roughly crushed green leaf of ginkgo is extracted with water or a water/ethanol mixture under heating to extract the water-soluble active component. The extracted liquid is mixed with a partial hydrolyzate of starch such as dextrin and glycosidase or trans-glycosidase having the activity to transfer the glucose group of the partial hydrolyzate of starch. The active component scarcely soluble or insoluble in water is subjected to the sugar transfer to a water-soluble glycoside and the glycoside is dissolved in the extracted liquid by this procedure. The dried extract is added to the extracted liquid and subjected to the process similar to the above process and the dissolved glycoside produced by this process is separated, purified and concentrated by conventional process to obtain the extract of the glycoside. The extraction efficiency of the active component can be improved and an easily absorbable glycoside having high absorption efficiency in living body can be produced by this process.
Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
This study investigated the anti-sarcopenic effect of fermented Tenebrio molitor larvae (mealworms) extract (FME) in both dexamethasone (DEX)-treated C2C12 cells and mice. FME (100 µg/mL) increased the diameter of myotubes and inhibited the gene and protein expression of atrogin-1 compared to DEX- or non-fermented mealworms extract (ME)-treated C2C12 cells. Male C57BL/6N mice were divided into five groups: Normal Control (NC), DEX (10 mg/kg, intraperitoneal), and three groups of DEX+FME (100, 200, or 500 mg FME/kg/day, oral) for two weeks. FME at doses of 200 and 500 mg/kg effectively improved grip strength when compared to the DEX group. Histological analysis of the quadriceps muscle showed a larger muscle fiber size in the DEX+FME groups compared to DEX group. FME (200 and 500 mg/kg) significantly increased cross-sectional area of the muscle fiber compared to DEX group. FME (500 mg/kg) significantly decreased the ubiquitin, atrogin-1 and MuRF-1 protein levels, and increased levels of MHC and MyoG in DEX-treated mice. The puromycin labeling assay revealed that FME increased protein synthesis in DEX-induced muscle atrophy. The FME treatment demonstrated significant upregulation in phosphorylation levels, including mTOR, FoxO3α, Akt, and PI3K compared to DEX group. In conclusion, FME inhibited the increase in proteins associated with muscle atrophy, including, atrogin-1 and MuRF-1, by regulating the PI3K-Akt-FoxO3α pathway. FME improved the PI3K-Akt-mTOR signaling pathway, which was reduced by DEX. This study suggests that FME has the potential for use in sarcopenia therapy, possibly serving as a natural agent that counteracts the negative effects of DEX on muscle tissue.
Bone cancer pain (BCP), due to cancer bone metastasis and bone destruction, is a common symptom of tumors, including breast, prostate, and lung tumors. Patients often experience severe pain without effective treatment. Here, using a mouse model of bone cancer, we report that MOTS-c, a novel mitochondrial-derived peptide, confers remarkable protection against cancer pain and bone destruction. Briefly, we find that the plasma level of endogenous MOTS-c is significantly lower in the BCP group than in the sham group. Accordingly, intraperitoneal administration of MOTS-c robustly attenuates bone cancer-induced pain. These effects are blocked by compound C, an AMPK inhibitor. Furthermore, MOTS-c treatment significantly enhances AMPKα 1/2 phosphorylation. Interestingly, mechanical studies indicate that at the spinal cord level, MOTS-c relieves pain by restoring mitochondrial biogenesis, suppressing microglial activation, and decreasing the production of inflammatory factors, which directly contribute to neuronal modulation. However, in the periphery, MOTS-c protects against local bone destruction by modulating osteoclast and immune cell function in the tumor microenvironment, providing long-term relief from cancer pain. Additionally, we find that chronic administration of MOTS-c has little effect on liver, renal, lipid or cardiac function in mice. In conclusion, MOTS-c improves BCP through peripheral and central synergistic effects on nociceptors, immune cells, and osteoclasts, providing a pharmacological and biological rationale for the development of mitochondrial peptide-based therapeutic agents for cancer-induced pain.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to implanted intra-lumen vascular medical devices for local delivery of therapeutic preparations or their combinations, and can be applied for prevention and treatment of stenosis or restenosis, developing, for instance, as a result of atherosclerosis, or transcutaneous transluminal coronary angioplasty. Claimed device- stent, contains spiral-shaped middle section, formed by sinusoidally located bearing construction elements in alternating order. Sinusoidally located bearing elements of said section form stable spiral-shaped module, connected by means of flexible hinges. Said section contains repeated threads of bearing element, which are geometrically symmetrical with respect to themselves. Said section also contains first and second ring-like end sections, formed by sinusoidally located bearing construction elements in alternating order, connected by means of flexible hinges. Spiral-shaped middle section also contains first and second transitional sections, formed by sinusoidally located bearing construction elements in alternating order, which form variable spiral-shaped module, connected by means of flexible hinges. First and second spiral-shaped transitional sections have construction elements, located in alternating order and connecting flexible hinges, which do not possess symmetry with respect to themselves. Fist and second ring-shaped end sections are connected to spiral-shaped middle section by means of first and second spiral-shaped transitional sections, respectively. At least, one of bearing construction elements contains, at least, one reservoir. At least, in one reservoir, there is composition, containing mTOR inhibitor and biodegradable polymer, releasing mTOR inhibitor in abluminal direction.EFFECT: invention makes it possible to retard stenosis and restenosis development, as non-symmetrical and alternating sections of device provide non-uniform development of connecting tissue, as well as provide delivery of preparation or combination of preparations, which are released locally mainly in parietal or abluminal direction.6 cl, 39 dwg, 7 tbl
CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.
Patients receive cisplatin and etoposide as in Arm A and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
Cardiac surgery is a high-risk elective surgical procedure frequently requiring CPB in which a machine pumps blood while the surgeon operates on the heart. CPB contributes to surgical risk by causing endothelial dysfunction and acute kidney injury (AKI). Endothelial dysfunction and AKI happen because heart lung machines typically generate non-pulsatile blood flow, which is abnormal and results in impaired tissue oxygen delivery. Normal blood flow is pulsatile due intermittent contraction and relaxation of the heart during the cardiac cycle, which produces a mechanical signal that induces endothelial cells to produce nitric oxide. Without nitric oxide, blood flow does not penetrate as deeply into organs such as the kidneys which leads to acute kidney injury. AKI increases mortality 10-fold after cardiac surgery placing many people at risk since over 400,000 people have surgery with CPB each year in the United States. Thus, pulsatile CPB may influence endothelial function and renal blood flow after cardiac surgery. This study will observe patients undergoing cardiac surgery with CPB and compare patients who receive pulsatile or non-pulsatile CPB.
This was a randomized, single-blinded, clinical study carried out at the Julio Muller University Hospital (Mato Grosso State, Brazil). This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects/patients were approved by the hospital Research Ethics Committee registered under number 697/CEP-HUJM/09. Written informed consent was obtained from all patients.

Except for the preoperative counseling which was received only by the intervention group, all patients received the same protocol of perioperative care.

The main endpoint of the study was the presence and the intensity of postoperative symptoms such as nausea, vomiting and pain. A questionnaire containing a visual analogue scale (VAS) was applied 24h after the operation to measure the intensity of postoperative pain, nausea and the well-being. The VAS consisted of a horizontal line, 100 mm in length, anchored by word descriptors at each end to represent the lowest and the highest intensity of all the symptoms analyzed. The patient was asked to mark in the straight line the point that most likely represents the symptom at the moment. The VAS score of each individual was determined by measuring in millimeters from the left end of the line to the point marked. The questions were: "how severe was your pain during this period of 24h after the operation?", "how severe was the intensity of your nausea during this period of 24h after the operation? ", and "how great is your well-being at the present moment". For the first two questions the words at each end of the line were "no pain" and "severe pain", and "no nausea" and "severe nausea". For the well-being question the words were "no well-being" and "greatest well-being". The Vomiting was also recorded as a categorical variable (yes or no). The length of stay and postoperative complications were also collected.
Poly(²-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are described. Methods of preparing these polymers from commercially available starting materials are also provided. These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the poly(amine) nature of these polymers, they are particularly suited for the delivery of polynucleotides. Nanoparticles containing polymer/polynucleotide complexes have been prepared. The inventive polymers may also be used to encapsulate other agents to be delivered. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings. A system for preparing and screening polymers in parallel using semi-automated robotic fluid delivery systems is also provided.
Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
A system and method for predicting medical outcomes of patients having a variety of diseases, and communicating these predicted outcomes to the patients. The system and method incorporates a plurality of variables and available medical treatments and/or therapies that are available to a patient. All of the variables and treatments are analyzed to predict medical outcomes without treatment, and with each of the plurality of available treatments. The system includes a graphical user interface for inputting the variables and the treatment options. This graphical user interface can comprise a plurality of toggle switches for manipulating each variable as desired. The graphical user interface can display a risk of complication of a disease, both with and without treatment, to a patient, thereby improving communication to the patient and providing healthcare providers and professionals with a procedure and system by which medical outcomes may be predicted and readily communicated to patient.
Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
FIELD: virology, biotechnology. SUBSTANCE: invention relates to strains of human immunodeficiency virus (HIV) of subtype B which are detected in 90% infected males and above 50% of infected females. New strain of HIV-1/Russia, GM-12-95 (RU 1295) is distributed in Russia regions in population of male homosexuals. Strain shows high reproductive activity, easily multiplied in neoplastic T-lymphoid cells MT-4 and SupT1 and good stored at -70 C. Strain HIV-1/Russia/ GM-12-95 (RU 1295) is identified by some independent procedures, polymerase chain reaction and analysis of nucleotide sequence of its genome. Strain has the following amino acid sequence of the region: CTRPNNNTRKRIHIGPGRAYFTGRIG- -DIRQAYC. The obtained strain is a suitable biotechnological natural model and can be used for preparing diagnostic and experimental vaccine preparations. EFFECT: strain indicated above. 4 tbl